Healthcare Jul 30, 2021 09:41 AM (GMT+8) · EqualOcean
Yiouda health learned on the 30th that Baiji Shenzhou announced that the BTK inhibitor baiyueze ®( The interim analysis of a global phase 3 seqoia trial of zebutinib) achieved positive main results, and the study reached the main end point. The data show that compared with chemical immunotherapy, Hyatt ® It significantly prolonged the progression free survival of newly treated patients with chronic lymphoblastic leukemia (CLL), and showed good safety and tolerance. It is worth noting that Sequoia is the best choice for Hyatt after the global phase 3 head-on Alpine study ® The second global phase 3 trial with positive results in CLL. Baiyueze ® It is a Btk small molecule inhibitor independently developed by Baiji Shenzhou scientists. At present, it is conducting extensive clinical trial projects all over the world as a single drug and in combination with other therapies to treat a variety of B-cell malignant tumors. Baiyueze ® Many indications have been approved in the United States, China, the United Arab Emirates, Canada, Israel and other countries or regions, and nearly 30 clinical trials have been carried out for 8 indications around the world. At present, there are more than 30 Baiyue Ze ® Relevant listing applications for multiple indications have been submitted, covering the EU and more than 20 other countries or regions. In China, Baiyue Ze ® It has been included in the national medical insurance catalogue and will take effect on March 1, 2021.